BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

Summary

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

Timeline

Start

2026-04-07

Primary completion

2028-04-07

Completion

2028-04-07

Drugs

Indications